Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites

Clicks: 527
ID: 113941
2011
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #22 of 545 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 545 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Sensitive rapid anti-HCV assays are appropriate and feasible for high-prevalence, high-risk populations such as PWID, who can be reached through social service settings such as syringe exchange programs and methadone maintenance treatment programs.
Reference Key
bd2011clinicalperformance Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Smith BD;Teshale E;Jewett A;Weinbaum CM;Neaigus A;Hagan H;Jenness SM;Melville SK;Burt R;Thiede H;Al-Tayyib A;Pannala PR;Miles IW;Oster AM;Smith A;Finlayson T;Bowles KE;Dinenno EA;;
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2011
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.